Matthew J. Klebanoff

Oct 18, 2024 | jamanetwork.com | Matthew J. Klebanoff |Paula Chatterjee

Introduction Real-time prescription benefit tools (RTBTs) display out-of-pocket drug cost estimates in the electronic health record (EHR) at the point of prescribing.1 RTBTs can help lower out-of-pocket drug spending.2 Since 2021, the Centers for Medicare & Medicaid Services have required Part D plan sponsors to implement RTBTs that can be incorporated into EHRs.3 However, health care facilities are not mandated to adopt RTBTs. Hospitals that serve patients who are economically and socially...

Jun 6, 2024 | jamanetwork.com | Matthew J. Klebanoff |John K. Lin

Adalimumab (Humira) is a top-selling drug in Medicare Part D, representing $4.7 billion of Medicare spending in 2021.1 This anti-inflammatory biologic lost US patent protection in 2023, and a number of manufacturers introduced biosimilar competitors (eTable in Supplement 1). Biosimilars could help lower spending on biologics for Medicare, just as generics have done for small-molecule drugs.